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Abstract
Background: The pharmacy reference database, Micromedex, lists concomitant 
hydrochlorothiazide and cyclophosphamide use as a potential major drug-drug-interaction (DDI) 
although only one small, single center study supports this claim. Our objective was to estimate 
associations between this potential DDI and two adverse chemotherapy-related events, 
neutropenia-related hospitalizations and treatment regimen discontinuation, among a cohort of 
women with breast cancer initiating adjuvant chemotherapy containing cyclophosphamide.
Methods: Using linked Surveillance, Epidemiology, and End Results program (SEER)-Medicare 
data, we included women 66 years and older with breast cancer diagnosis between 2007-2011 who 
initiated a regimen containing cyclophosphamide. Risk ratios (RRs) and 95% confidence intervals 
for adverse outcomes comparing women exposed versus unexposed to the potential DDI were 
assessed using modified multivariable Poisson regression adjusting for potential confounders.
Results: In total, 27% of women receiving cyclophosphamide treatment were exposed to 
concomitant hydrochlorothiazide, of which 11% experienced a neutropenia-related hospitalization 
and 21% discontinued their chemotherapy regimen prior to completion. Adjusted risks of both 
adverse events were similar between those exposed and unexposed to the potential DDI 
(neutropenia-related hospitalization: adjusted RR=0.92 (0.70, 1.21); treatment discontinuation: 
aRR=1.00 (0.96, 1.05)).
Conclusions: Our results do not support an association between concomitant 
hydrochlorothiazide use and two clinically relevant adverse chemotherapy-related events.
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Impact: Our results support re-assessing and potentially lowering severity of this potential 
interaction in drug reference databases.
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Introduction
Cyclophosphamide is a preferred agent in breast cancer treatment,(1) and 
hydrochlorothiazide, a drug used to treat hypertension, is one of the most commonly used 
medications in the United States.(2,3) Pharmacy reference databases such as Micromedex(4) 
list hydrocholorothiazide and cyclophosphamide as a significant drug-drug-interaction 
(DDI). However, this claim is supported by one study from 1981, including 14 women 
receiving breast cancer treatment and also taking a thiazide diuretic for hypertension.(5) 
This study found that white blood cell counts, assessed weekly, were notably lower in cycles 
where women were treated with thiazide diuretics versus cycles where the same women 
were treated with other blood pressure medications (reserpine or propanolol), raising 
concerns that thiazide diuretics may enhance the myelosuppressive effects of chemotherapy.
(5) No studies to date have evaluated clinical outcomes of this potential DDI in a large 
population of women with breast cancer.
Objective
We aimed to estimate associations between concomitant hydrochlorothiazide use and 
adverse clinical outcomes (neutropenia-related hospitalizations and chemotherapy 
discontinuation) among older women with breast cancer treated with cyclophosphamide.
Materials and Methods
Study population
Using linked Surveillance, Epidemiology, and End Results program (SEER)-Medicare data, 
we identified women aged 66 years and older with an incident, first, primary breast cancer 
diagnosed between 2007-2011 who underwent surgery within 90 days of diagnosis, did not 
receive neoadjuvant chemotherapy, and initiated adjuvant chemotherapy containing 
cyclophosphamide within 120 days of surgery. All women had to have continuous Medicare 
Parts A, B, and D coverage and be alive from 12 months before through 12 months 
following surgical resection. Only women initiating a cyclophosphamide-containing regimen 
were included.
Healthcare Common Procedural Coding System codes were used to identify specific 
intravenously administered chemotherapeutic agents, including cyclophosphamide, 
docetaxel, doxorubicin, epirubicin, fluorouracil, methotrexate, and paclitaxel. National Drug 
Codes from Medicare Part D files were used to capture outpatient fills for oral 
cyclophosphamide and hydrochlorothiazide.
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National Comprehensive Cancer Network (NCCN) guidelines were used to determine 
recommended regimens and number of cycles. Initial treatment regimen was identified using 
the first combination of chemotherapy agents with claims on the same date or within 3 days. 
The 3-day window was used to account for slight delays in therapy receipt and 
administrative processing. Patients were classified based on the first drug combination 
received; thus, all patients receiving adriamycin/cyclophosphamide (AC) without a 
concurrent taxane drug were categorized as AC patients regardless of whether taxane was 
received subsequently. For the oral cyclophosphamide-containing regimen, CMF, 
cyclophosphamide claims needed to be within 28+3 days of the intravenous chemotherapy 
claim dates. Twenty-eight days was selected based on the cycle length for the regimen.
When there were multiple claim dates, the earliest claim date for any chemotherapy agent in 
the regimen was assigned as the cycle start date. Patients were assigned to regimen groups 
based on their first regimen. Cycle count was determined by summing each time the regimen 
was observed in the 12 months following surgery.
Exposure and outcome
The exposure, concomitant hydrochlorothiazide use, was defined using Medicare Part D 
files as any overlap in days’ supply and initiation of the first cycle of adjuvant chemotherapy 
(i.e., 1 or more days of overlap). The first outcome, neutropenia-related hospitalization, was 
defined using International Classification of Diseases, Clinical Modification, 9th Edition 
(ICD-9) diagnosis codes 284.1X, 288.00, 288.03, or 288.09 present within six months of 
chemotherapy initiation. The secondary outcome, chemotherapy discontinuation, was 
defined by whether or not individuals completed the recommended number of cycles for 
their specific regimen based on NCCN Guidelines1 within 12 months from surgery. Gaps in 
treatment of over 90 days were also considered treatment discontinuation.
Statistical analysis
Associations between the potential DDI and adverse outcomes were assessed using modified 
Poisson regression to overcome convergence issues with log binomial regression. Robust 
error variance estimation was used to compute 95% confidence intervals.(6) The following 
covariates were included for adjustment in the regression model: colony stimulating factor 
(CSF) use, age and stage at diagnosis, race, treatment regimen, and Charlson comorbidity 
score classified as 0, 1, and 2+. Treatment regimens included TC (docetaxel + 
cyclophosphamide or paclitaxel + cyclophosphamide or paclitaxel + docetaxel + 
cyclophosphamide), AC (doxorubicin + cyclophosphamide), CMF (cyclophosphamide (oral) 
+ methotrexate + fluorouracil), dose-dense AC (doxorubicin + cyclophosphamide + colony 
stimulating factor), and a grouping of other regimens that were less frequent, including EC 
(epirubicin + cyclophosphamide), TAC (docetaxel + doxorubicin + cyclophosphamide), and 
CEF (cyclophosphamide + epirubicin + fluorouracil).
CSF, prescribed to prevent neutropenia, was defined using prescription or administration 
claims within 7 days of the initial chemotherapy cycle. Effect measure modification by CSF 
use and age (75+ vs. <75 years) were explored.
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This study received institutional review board approval from the University of North 
Carolina at Chapel Hill.
Results
In total, 2,136 women initiated adjuvant chemotherapy containing cyclophosphamide for 
stage I-III breast cancer. Overall, 581 women (27%) were concomitantly exposed to 
hydrochlorothiazide at adjuvant chemotherapy initation. Patient characteristics were similar 
among women exposed and unexposed to hydrochlorothiazide (Table 1).
Only 227 (11%) women were hospitalized with a diagnosis code for neutropenia and 447 
(21%) discontinued adjuvant chemotherapy before completion (Table 2). Overall, exposure 
to concomitant hydrochlorothizide was neither associated with neutropenia-related 
hospitalization (aRR=0.92 (0.70, 1.21)) nor chemotherapy discontinuation (aRR=1.00 (0.96, 
1.05)). There was no evidence of effect measure modification by CSF use or age.
Discussion
Using linked SEER-Medicare data, we observed no association between concomitant 
hydrochlorothiazide and cyclophosphamide use and either neutropenia-related 
hospitalization or treatment discontinuation. Our study included 2,136 women and is the 
largest investigation of this potential DDI to date, in contrast to the study by Orr,(5) which 
included only 14 patients. The large sample size increased precision of our estimates and 
provided the opportunity to investigate effect measure modification in key subgroups.
Our study is subject to limitations. First, it is plausible that knowing about the potential DDI, 
oncologists might recommend discontinuation of hydrocholothiazide in women planning to 
take or taking cyclophosphamide, leading to exposure misclassification that could attenuate 
observed associations. In our study, the proportion of women concomitantly exposed to 
hydrochlorothiazide (27%) is comparable to that of the general population of adults age 65 
and over,(2) among whom 20% receive thiazide monotherapy and 11% have combination 
antihypertensive use, often including hydrochlorothiazide.(2) In addition, we found that 92% 
of patients had >1 hydrochlorothiazide dispensing following chemotherapy initiation, 
suggesting continued use of hydrochlorothiazide during treatment. Thus, it does not appear 
as though oncologists are reacting to the potential DDI. Second, body mass index (BMI) is 
not available in claims data and could potentially lead to an attenuation in the observed 
associations, if women with higher BMI are underdosed and are more likely to use 
hydrochlorothiazide. Third, our data are also limited by the lack of laboratory data, which 
could provide more direct measures of the outcome of interest, such as absolute neutrophil 
count. If patient-reported outcomes were available, it would be interesting to examine levels 
of fatigue or other signs of neutropenia.
A recent working group(7) with expertise in pharmacology, drug information, informatics, 
and clinical decision support found there was little high quality evidence to support many 
DDIs, and that compendia and pharmacy database editors do not have a standard guideline 
or methodology to identify DDIs. The findings from this study could inform pharmacy 
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reference database DDI updates and we suggest reducing the severity level applied to the 
potential DDI between hydrochlorothiazide and cyclophosphamide.
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TAC docetaxel + doxorubicin + cyclophosphamide
CEF cyclophosphamide + epirubicin + fluorouracil
BMI body mass index
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Table 1.
Patient characteristics of study population by concomitant hydrochlorothiazide exposure
HCTZ, N (%) No HCTZ, N (%)
Total 581 1555
Age at diagnosis (mean (SD)) 71.5 (4.5) 71.2 (4.4)
Age category
 66-69 years 236 (40.2) 681 (43.8)
 70-74 years 211 (35.7) 539 (34.7)
 75-79 years 97 (17.3) 249 (16.0)
 80+ years 37 (6.4) 86 (5.5)
Race
 White 455 (78.3) 1308 (84.1)
 Black 87 (15.0) 128 (8.2)
 Other 39 (6.7) 119 (7.7)
Stage at diagnosis
 I 133 (22.9) 359 (23.1)
 II 328 (56.5) 826 (53.1)
 III 120 (20.7) 370 (23.8)
Charlson Comorbidity Score
 0 333 (57.3) 970 (62.4)
 1 164 (28.2) 386 (24.8)
 2+ 84 (14.5) 199 (12.8)
Regimen*
 TC 295 (50.8) 824 (53.0)
 AC 54 (9.3) 165 (10.6)
 CMF 48 (8.3) 111 (7.1)
 DD-AC 148 (25.5) 365 (23.5)
 Other 36 (6.2) 90 (5.8)
Colony stimulating factor (CSF)
 No 193 (33.2) 510 (32.8)
 Yes 388 (66.8) 1045 (67.2)
*
Regimens include TC (docetaxel + cyclophosphamide or paclitaxel + cyclophosphamide or paclitaxel + docetaxel + cyclophosphamide), AC 
(doxorubicin + cyclophosphamide), CMF (cyclophosphamide (oral) + methotrexate + fluorouracil), dose-dense AC (doxorubicin + 
cyclophosphamide + colony stimulating factor), and Other which includes EC (epirubicin + cyclophosphamide), TAC (docetaxel + doxorubicin + 
cyclophosphamide), and CEF (cyclophosphamide + epirubicin + fluorouracil).
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